CEP55 Promotes Acral Melanoma Progression via MAPK Pathway and Predicts Survival Following Immunotherapy
Oncology Research · 2025
DOI: 10.32604/or.2025.064780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Meng Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, 210042, China. Hauptthemen laut MEDLINE: Melanoma, Cell Cycle Proteins, Immunotherapy, MAP Kinase Signaling System. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, 210042, China.
Zitieren
APA
Cao, M., Zhang, R., Hong, A., Ye, S., Qiu, Z., Li, D., Lin, T., & Wang, Y. (2025). CEP55 Promotes Acral Melanoma Progression via MAPK Pathway and Predicts Survival Following Immunotherapy. Oncology Research. https://doi.org/10.32604/or.2025.064780
Vancouver
Cao M, Zhang R, Hong A, Ye S, Qiu Z, Li D, et al. CEP55 Promotes Acral Melanoma Progression via MAPK Pathway and Predicts Survival Following Immunotherapy. Oncology Research. 2025. doi:10.32604/or.2025.064780
BibTeX
@article{Cao2025,
author = {Cao, Meng and Zhang, Rundong and Hong, Anlan and Ye, Shanyuan and Qiu, Zequn and Li, Dongqing and Lin, Tong and Wang, Yan},
title = {CEP55 Promotes Acral Melanoma Progression via MAPK Pathway and Predicts Survival Following Immunotherapy},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2025.064780}
}
EUVIMED